Therapeutic Drug Monitoring

Newer Drugs and Biomarkers

Edited by

  • Amitava Dasgupta, Professor, Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX, USA

Therapeutic Drug Monitoring: Newer Drugs and Biomarkers features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presents new and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists, toxicologists, clinical chemists, laboratory professionals and physicians, this book is an essential resource on the current practice of therapeutic drug monitoring in improving patient safety.
View full description

Audience

The primary target market for this book includes clinical pathologists, toxicologists, pharmacologists, laboratory professionals and clinical chemists.

 

Book information

  • Published: June 2012
  • Imprint: ACADEMIC PRESS
  • ISBN: 978-0-12-385467-4


Table of Contents

Chapter 1. Introduction to Therapeutic Drug Monitoring: Frequently and Less Frequently Monitored Drugs

Amitava Dasgupta, Ph.D.

Chapter 2. Effects of Pre-Analytical Variables in Therapeutic Drug Monitoring

Valerie Bush, Ph.D.

Chapter 3. Analytical Techniques used in Therapeutic Drug Monitoring

Michael C. Milone, MD, Ph.D.

Chapter 4. Clinical Utility of Free Drug Monitoring

Marcel Musteata, Ph.D.

Chapter 5. Current Practice of Therapeutic Drug Monitoring: Dose Adjustment of Drugs using Pharmacokinetic models

Franck Saint-Marcoux, Ph.D.

Chapter 6. An Introduction to Personalized Medicine

Annjanette Stone, B.S. and Joshua Bornhorst, Ph.D.

Chapter 7. Application of Ultra-High Throughput Sequencing and Microarray Technologies in Pharmacogenomics Testing

Gary Hardiman, Ph.D.

Chapter 8. Pharmacogenomics and Warfarin therapy

Jenny Martin, PharmD. and Andre Somogyi, PharmD.

Chapter 9. Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection: Example of Antibiotic Therapy Management

Jill Butterfield, PharmD., Thomas P. Lodise, Jr., PharmD., Manjunath P. Pai, PharmD.

Chapter 10. Guidelines for Monitoring of Vancomycin, Aminoglycosides and certain antibiotics

Ronald W. McLawhon, M.D., Ph.D.

Chapter 11. Challenges in Therapeutic Drug Monitoring of Digoxin and other Antiarrhythmic Drugs

Amitava Dasgupta, Ph.D.

Chapter 12. Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants

Matthew Luke, M.D., University of New Mexico. Albuquerque, NM

Chapter 13. Challenges in Therapeutic Drug Monitoring of Classical Tricyclic and Newer Antidepressants: Analytical and Pharmacogenetics Considerations

Uttam Garg, Ph.D. and Angela Ferguson, Ph.D.

Chapter14. Therapeutic Drug Monitoring of Selected Anticancer Drugs: Pharmacogenomics issues

Michael C. Milone, MD, Ph.D.

Chapter 15. Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass Spectrometry

Kathleen A. Kelly, Ph.D. and Anthony W. Butch, Ph.D.

Chapter 16. Biomarkers: The Link between Therapeutic Drug Monitoring and Pharmacodynamics of Immunosuppressants

Michael Oellerich, M.D., Gunnar Brandhorst, M.D., Maria Shipkova, M.D., Eberhard Wieland, M.D.

Chapter 17. Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Infection

Natella Y. Rakhmanina, MD, PhD., Charles J.L. la Porte, PharmD., Ph.D.

Chapter 18. Drug Testing in Pain Management

Roger L. Bertholf, Ph.D., and Gary M. Reisfield, MD

Chapter 19. Role of Therapeutic Drug Monitoring to Identify Clinically Significant Drug-Herbal Supplement Interaction

Alex C. Chin, Ph.D., Leland B. Baskin, M.D.